ReVOLT: radiation-enhanced viral oncolytic therapy.
Viral oncolytic therapy has been pursued with renewed interest as the molecular basis of carcinogenesis and viral replication has been elucidated. Genetically engineered, attenuated viruses have been rationally constructed to achieve a therapeutic index in tumor cells compared with surrounding normal tissue. Many of these attenuated mutant viruses have entered clinical trials. Here we review the preclinical literature demonstrating the interaction of oncolytic viruses with ionizing radiation and provides a basis for future clinical trials.
Advani
Sunil J
SJ
Department of Radiation and Cellular Oncology, the University of Chicago, Chicago, IL 60637, USA.
Mezhir
James J
JJ
Roizman
Bernard
B
Weichselbaum
Ralph R
RR
D000256:Adenoviridae / Q000502:physiology / Q000528:radiation effects; D000818:Animals; D015316:Genetic Therapy / Q000379:methods*; D005909:Glioblastoma / Q000628:therapy; D018259:Herpesvirus 1, Human / Q000502:physiology / Q000528:radiation effects; D006801:Humans; D009369:Neoplasms / Q000628:therapy* / Q000821:virology; D050130:Oncolytic Virotherapy / Q000379:methods*; D050504:Oncolytic Viruses / Q000502:physiology / Q000528:radiation effects; D011839:Radiation, Ionizing; D014779:Virus Replication / Q000528:radiation effects